Pfizer Nears $7.3B Acquisition of Metsera in Weight-Loss Drug Market Push

Metsera (MTSR) stock surged over 50% in pre-market trading after reports emerged that Pfizer (PFE) is close to finalizing a $7.3 billion acquisition. The deal, which could be announced as early as Monday, includes $47.50 per share in cash and an additional $22.50 contingent on performance milestones—a 42.5% premium to Metsera's Friday closing price of $33.32.

Pfizer's MOVE signals its strategic pivot toward the booming weight-loss drug market, following the underwhelming clinical trial results of its experimental pill, danuglipron. The pharmaceutical giant has been aggressively expanding through acquisitions, including last year's $43 billion purchase of oncology-focused Seagen.

Metsera, a recent entrant to the public markets, specializes in weight-loss therapeutics—a sector attracting intense investor interest amid rising global demand for anti-obesity treatments.